menu
    • menu
    [{"orgOrder":0,"company":"Vilya","sponsor":"Vilya","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Macrocyclic Peptide","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Vilya","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vilya \/ Vilya","highestDevelopmentStatusID":"3","companyTruncated":"Vilya \/ Vilya"},{"orgOrder":0,"company":"Vilya","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Vilya","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Vilya \/ Arch Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Vilya \/ Arch Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Vilya

    Menu

    Vilya

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vilya

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Vilya

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrocyclic Peptide

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : Institute for Protein Design

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vilya Licenses RFdiffusion Model from UW for Macrocyclic Peptide Design

                            Details : The agreement aims to use RFpeptides, a new molecular design technology which provides Vilya with powerful structure prediction framework for unique design of potent and selective macrocycles.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : Macrocyclic Peptide

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : Institute for Protein Design

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vilya

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Vilya

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Arch Ventures

                            Deal Size : $71.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Vilya Expands Series A Financing to $71 Million for Computational Drug Design Advancements

                            Details : The proceeds will advance Vilya's proprietary computational drug design and development platform and its pipeline of novel macrocycles that precisely target disease biology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 04, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Arch Ventures

                            Deal Size : $71.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth